A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation

BACKGROUND: The purpose of this study was to test the efficacy and safety of daclizumab (DZM) versus anti-thymocyte globulin (ATG) as a component of induction therapy in heart transplant recipients. METHODS: Thirty heart transplant patients were randomized to receive either ATG or DZM during inducti...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Mullen, John C, Kuurstra, Emily J, Oreopoulos, Antigone, Bentley, Michael J, Wang, Shaohua
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2014
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4120716/
https://ncbi.nlm.nih.gov/pubmed/25093077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2047-1440-3-14
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items